Brand Name: Halaven®
Eribulin is used in the treatment of certain types of breast cancer.
Eribulin is a type of chemotherapy. Specifically, this medication is in a class of drugs called microtubule dynamics inhibitors. It works by interfering with the process of cell division, thereby slowing or stopping the spread of cancer.
This medication is given as infusion into a vein (intravenous). Each infusion takes approximately 2 to 5 minutes. Usually, eribulin is given on days 1 and 8 of a 21-day cycle. The exact dose and schedule depends on how well the cancer is responding to the drug and several other factors. Your doctor will determine the approach that is best for you.
Eribulin side effects
To prevent problematic interactions between eribulin and other drugs, be sure to tell your doctor if you are allergic to any medications, and what other medications and supplements you are currently taking. You should also inform your doctor if you have or ever had liver tumor, liver disease, kidney disease, or Long QT syndrome, are pregnant, planning to become pregnant, or are breastfeeding. Talk with your doctor before having surgery, including dental surgery, during treatment with eribulin.
Possible side effects of eribulin may include:
- Loss of appetite
- Weight loss
- Bone, back, or joint pain
- Hair loss
Some eribulin’s side effects can be serious. Call your doctor immediately if you experience any of these symptoms:
- Fever, chills, sore throat, or other signs of infection
- Numbness, burning, or tingling in the arms, legs, hands, or feet
- Pale skin
- Shortness of breath
- Irregular heartbeat
Please note that this is not a comprehensive list. Patients may experience additional effects not mentioned above.
At Cancer Treatment Centers of America (CTCA), your team of cancer experts will explain each of the side effects of eribulin with you in detail, as well as the side effects and expectations of all other medications planned as part of your individualized treatment plan.
Eribulin for cancer treatment
Eribulin is approved by the FDA for the treatment of:
- Metastatic breast cancer after at least two chemotherapy treatment regimens with an anthracycline and a taxane.
At Cancer Treatment Centers of America (CTCA), our integrative approach to cancer treatment works to fight your disease on all fronts and ensures that you remain at the center of everything we do. We encourage participation from both you and your family to make certain you are comfortable with all decisions made regarding your treatment.